Elevated synaptic levels of dopamine may induce striatal neurodegeneration in L-DOPA-unresponsive parkinsonism subtype of multiple system atrophy (MSA-P subtype), multiple system atrophy, and methamphetamine addiction. We examined the participation of dopamine and D1 dopamine receptors in the genesis of postsynaptic neurodegeneration. Chronic treatment of human SK-N-MC neuroblastoma cells with dopamine or H 2 O 2 increased NO production and accelerated cytotoxicity, as indexed by enhanced nitrite levels and cell death. The antioxidant sodium metabisulfite or SCH 23390, a D1 dopamine receptor-selective antagonist, partially blocked dopamine effects but together ablated dopamine-mediated cytotoxicity, indicating the participation of both autoxidation and D1 receptor stimulation. Direct activation of D1 dopamine receptors with SKF R-38393 caused cytotoxicity, which was refractory to sodium metabisulfite. Dopamine and SKF R-38393 induced overexpression of the nitric-oxide synthase (NOS) isoforms neuronal NOS, inducible NOS (iNOS), and endothelial NOS in a protein kinase A-dependent manner. Functional studies showed that ϳ60% of total NOS activity was due to activation of iNOS. The NOS inhibitor N(G)-nitro-L-arginine methyl ester and genistein, wortmannin, or NF-B SN50, inhibitors of protein tyrosine kinases phosphatidylinositol 3-kinase and NF-B, respectively, reduced nitrite production by dopamine and SKF R-38393 but were less effective in attenuating H 2 O 2 -mediated effects. In rat striatal neurons, dopamine and SKF R-38393, but not H 2 O 2 , accelerated cell death through increased expression of neuronal NOS and iNOS but not endothelial NOS. These data demonstrate a novel pathway of dopamine-mediated postsynaptic oxidative stress and cell death through direct activation of NOS enzymes by D1 dopamine receptors and its associated signaling pathways.Striatonigral neurodegeneration is implicated in the clinical expression of several human disorders and addictive states involving dopamine neuronal dysfunction, such as MSA, 1 L-DOPA-unresponsive parkinsonism subtype of multiple system atrophy (MSA-P subtype) (1), secondary dopamine dysfunction in Huntington's disease (HD), and methamphetamine (METH)-induced neurotoxicity (2, 3), in which dopaminergic transmission is interrupted by progressive loss of striatal neurons bearing postsynaptic D1 and D2 dopamine receptors (4). Moreover, striatonigral neurodegeneration was also observed in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or 3-nitropropionic acid (5). Recent studies implicate the participation of both reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the pathophysiology of striatonigral neurodegeneration (5-8) through mechanisms that remain undefined.Because striatal neurons do not produce dopamine or express the dopamine transporter (DAT), the mechanism of dopaminemediated neurotoxicity in such neurons occurs through extracellularly present dopamine in the synapse (9, 10). Normally, dopamine released into the synapse is r...